A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Slides:

Advertisements

Similar presentations

Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden Featured Article: Tom W.C. Lung, Dennis Petrie, William.

Advertisements

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the.

with undiagnosed diabetes mellitus by three diagnostic criteria

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Selected efficacy and safety parameters.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Cumulative incidences of events, according to glucose-control strategy

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Group differences (DKA vs

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

A: PPG increment at week 26 for mealtime faster aspart versus IAsp.

Interaction of updated mean serial HbA1c and serum triglyceride levels with sensory peripheral neuropathy over 7 years in 151 type 2 diabetic participants.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Shown are cumulative incidence curves of TNNHS and DPT-1 participants who either had DPTRS values >7.00 (A) or dysglycemia (B). Shown are cumulative incidence.

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

(A) Hemoglobin A1c (HbA1c) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (B) Urinary albumin to creatinine.

A1C (A) and serum glycated albumin (GA) (B) levels in 47 pregnant women (study 1) divided according to gestational period into group I (21–24 weeks; n.

Stratified analysis of the association between GDM and abdominal circumference (AC) >90th percentile at 28 wkGA. Stratified analysis of the association.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Trajectories over the 9 years of follow-up of HbA1c in all participants (n = 4,080 at baseline), stratified by the presence of a family history of diabetes,

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effect of empagliflozin on efficacy parameters at week 18.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Glycemic control and body weight over 52 weeks.

Difference in average school grades between offspring born to women with type 1 diabetes and the matched control children, by maternal third trimester.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

A: Probability of SICH by baseline glucose level.

Mean (± SE) plasma glucose concentrations, symptom scores, plasma epinephrine and glucagon concentrations, and relative rCBF (as measured by PET counts)

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Example of how quantitative variables displaying a nonhomogeneous risk in visual display were split in high- and low-risk categories. Example of how quantitative.

Plots of average estimated and measured GFR vs

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Incidences of transitions between glycemic states by 25-OHD level.

Postoperative blood glucose levels and total insulin requirement.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

OR for cerebral infarction in groups stratified on the basis of “unfavorable” proatherothrombotic alleles. OR for cerebral infarction in groups stratified.

The risk for incident cognitive dysfunction after an episode of severe (A) or nonsevere (B) hypoglycemia with and without accounting for the competing.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs. A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs. Gla-100 during the 6-month treatment period. B: Cumulative mean number of nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemic events per participant during the 6-month treatment period. C: Estimated number of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe events per participant-year from week 9 to month 6 according to HbA1c at month 6. D: Cumulative mean number of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemic events per participant at any time (24 h) during the 6-month treatment period. E: Percentage of participants with one or more confirmed or severe hypoglycemic events by time of day during the 6-month treatment period. Data for safety population. Hannele Yki-Järvinen et al. Dia Care 2014;37:3235-3243 ©2014 by American Diabetes Association